Pleural Bleomycin vs Mechanical Abrasion in Malignant Pleural Effusion

Launched by ASSIUT UNIVERSITY · Nov 13, 2024

Keywords

ClinConnect Summary

This clinical trial is comparing two different treatments for a condition called malignant pleural effusion, which is when fluid builds up in the space around the lungs due to cancer. The trial will look at the effectiveness of pleural abrasion, a procedure done with a special instrument during a lung examination, versus using a medication called bleomycin that is injected into the pleural space through a catheter (a thin tube). The goal is to see which treatment works better in helping patients breathe easier and improve their quality of life.

To be eligible for this trial, patients need to be at least 18 years old and have a significant amount of fluid buildup that requires frequent draining. However, those who are not healthy enough for the procedure or have a very short life expectancy, among other specific conditions, will not be able to participate. If you join the trial, you can expect to receive one of the two treatments and be closely monitored by healthcare professionals. This study is still in the planning stages and is not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who are 18 years old or more.
• • patients with rapidly accumulating moderate \& massive malignant pleural. effusion that need frequent aspiration to relieve dyspnea and affect quality of life of the patient.
• Exclusion Criteria:
• • patients not fit for thoracoscoy.
• • patients with life expectency less than 1 month .
• • trapped lung (endobronchial lesion).
• • excessive pleural adhesios.
• • mild effusion not need frequent aspiration and not affect
• • quality of life .
• • patients with chest infection : pneumonia , empyema .
• • patients with performance status that doesn't expected to increase by 1